Signaling pathway mechanisms in pancreatic ductal adenocarcinoma tumor microenvironment and emerging targeting strategies for improved prognosis
Oncology Reviews · 29.05.2026 · 20
DOI: 10.3389/or.2026.1814540 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Oncology Reviews, online erschienen am 29.05.2026. Verfasst von Tosin Akinsipe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 316 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by a dense desmoplastic stroma and a profoundly immunosuppressive tumor microenvironment (TME). The TME plays a major role in tumor progression, metastasis, and resistance to conventional therapies through a network of dysregulated signaling pathways, including KRAS, PI3K/AKT/mTOR, Raf/MAPK/ERK, TGF-β, NF-κB, Notch and Hedgehog. Moreover, cellular components such as cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), and regulatory T cells (Tregs) drive immune evasion and therapeutic resistance via cytokine signaling axes, including IL-6/STAT3 and CXCL12/CXCR4. Recent advances in nanomedicine have introduced polymeric nanoparticles as promising delivery vehicles for targeted disruption of these aberrant pathways. Polymeric nanoparticles are engineered to enhance bioavailability, tissue penetration, and selective delivery, co-deliver small-molecule inhibitors, siRNA, or immunomodulatory agents directly to the TME. This approach offers a strategy to overcome biological barriers, reprogram the stroma, and sensitize tumors to immunotherapy and chemotherapy. This review comprehensively examines the signaling mechanisms of PDAC in the TME, discusses current therapeutic strategies targeting these pathways, highlights challenges, including resistance and adverse effects, and explores future directions to optimize pancreatic cancer treatment by modulating this key signaling axis with nanomedicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA, United States.
- Department of Biological Sciences, Florida A&M University, Tallahassee, FL, United States.
- Department of Chemistry, Florida A&M University, Tallahassee, FL, United States.
- Department of Health Sciences, Florida A&M University, Tallahassee, FL, United States.
Zitieren
APA
Akinsipe, T., Odewumi, C. O., Latinwo, L., Aghimien, O. O., Musa, M. A., Igbinoba, P. O., Simons, A. L., & Aghimien, M. O. (2026). Signaling pathway mechanisms in pancreatic ductal adenocarcinoma tumor microenvironment and emerging targeting strategies for improved prognosis. Oncology Reviews, 20. https://doi.org/10.3389/or.2026.1814540
Vancouver
Akinsipe T, Odewumi CO, Latinwo L, Aghimien OO, Musa MA, Igbinoba PO, et al. Signaling pathway mechanisms in pancreatic ductal adenocarcinoma tumor microenvironment and emerging targeting strategies for improved prognosis. Oncology Reviews. 2026;20. doi:10.3389/or.2026.1814540
BibTeX
@article{Akinsipe2026,
author = {Akinsipe, Tosin and Odewumi, Caroline O and Latinwo, Lekan and Aghimien, Omorose O and Musa, Musiliyu A and Igbinoba, Philip O and Simons, Anthony L and Aghimien, Monica O},
title = {Signaling pathway mechanisms in pancreatic ductal adenocarcinoma tumor microenvironment and emerging targeting strategies for improved prognosis},
journal = {Oncology Reviews},
year = {2026},
volume = {20},
doi = {10.3389/or.2026.1814540}
}
EUVIMED